TrialNature communications2026

Talimogene laherparepvec and atezolizumab in HER2-negative breast cancer following neoadjuvant chemotherapy: a window-of-opportunity phase II trial (SOLTI-1503 PROMETEO).

Tomás Pascual et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.